Skip to content
OpenCapital
Get started

Pacira BioSciences, Inc. PCRX Business Segments — Adjusted research and development

Similar metrics at other companies

Open Text logo
OTEXReportable Segment — Adjusted research and development
$168.38M-12.6%
Remitly Global, Inc. logo
RELYReportable segment — Research and Development Expense, Adjusted
$62.45M+18.7%
Paylocity logo
PCTYReportable Segment — Research and Development Expense, Adjusted
$44.98M+8.1%
Cloudflare, Inc. logo
NETReportable Segment — Research And Development Expense, Adjusted
$101.47M+32.1%
Zoom Video Communications, Inc. logo
ZMReportable Segment — Adjusted research and development
$153.11M+20.5%
UiPath logo
PATHReportable Segment — Adjusted research and development
$67.72M+12.5%

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$942.78M-16.0%
Enterprise value$1.21B+1.2%
P/E183.5×—
P/S1.3×-0.3×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%—
Net margin0.7%—
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%—
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept pcrx:ResearchAndDevelopmentAdjusted.

The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacira BioSciences, Inc.'s business segments — adjusted research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pacira BioSciences, Inc.'s business segments — adjusted research and development?
Pacira BioSciences, Inc. (PCRX) reported business segments — adjusted research and development of $25.36M in Q1 2026.
How has Pacira BioSciences, Inc.'s business segments — adjusted research and development changed year-over-year?
Pacira BioSciences, Inc.'s business segments — adjusted research and development increased by 9.8% year-over-year, from $23.1M to $25.36M.
What is the long-term trend for Pacira BioSciences, Inc.'s business segments — adjusted research and development?
Over 3 years (2022 to 2025), Pacira BioSciences, Inc.'s business segments — adjusted research and development has grown at a 10.2% compound annual growth rate (CAGR), from $78.2M to $104.7M.
What does business segments — adjusted research and development mean?
Captures the adjusted expenses incurred by the segment for research and development activities, excluding non-recurring charges. This metric reflects the company's commitment to innovation and the long-term pipeline development within this specific business area.